Akèy › Lukemi lenfositè kwonik › Missouri › Kansas City
Etid klinik pou Lukemi lenfositè kwonik nan Kansas City, MO
10 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Ap rekriteFaz 3
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- ak 1 plis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- ak 2 plis
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Ap rekriteFaz 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- The University of Kansas Cancer Center, Westwood · 5 mi lwen
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Ap rekriteFaz 3
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- University of Kansas, Westwood · 5 mi lwen
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 2
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- New York City, NY18 etid
- Rochester, MN18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Chicago, IL14 etid
- Cincinnati, OH14 etid
Lòt etid nan Kansas City
- Kansè nan tete34 etid
- Kansè Poumon ki pa ti selil31 etid
- Ensifizyans kadyak25 etid
- Kansè (tout kalite)21 etid
- Kansè poumon19 etid
- Kansè kolorektal16 etid
- Kansè Metastatik15 etid
- Leksemi mieloïd egi15 etid
- Kansè pwostat14 etid
- Kansè ovè11 etid
- Obèsite11 etid
- Dyabèt Tip 211 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.